Stock PRTA PROTHENA CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 16:47:25 29/04/2024 BST 		5-day change 1st Jan Change
21.82 USD +4.53% Intraday chart for Prothena Corporation plc +3.57% -39.32%
03-04 Prothena Names David Ford as Chief People Officer MT
03-04 Prothena Appoints David Ford to Newly Created Chief People Officer CI

Business Summary

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Number of employees: 173

Sales per Business

USD in Million2022Weight2023Weight Delta
Collaboration
99.9 %
14 25.7 % 91 99.9 % +559.11%
License and Intellectual Property
0.1 %
40 74.3 % 0 0.1 % -99.88%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
54 100.0 % 91 100.0 % +69.41%

Managers

Managers TitleAgeSince
Gene Kinney CEO
 Chief Executive Officer 55 30/11/12
Tran Nguyen DFI
 Director of Finance/CFO 50 28/02/13
Wagner M. Zago CTO
 Chief Tech/Sci/R&D Officer 51 31/12/11
Brandon Smith COO
 Chief Operating Officer 50 02/03/20
Hideki Garren CTO
 Chief Tech/Sci/R&D Officer 60 04/04/21
Randy Fawcett IRO
 Public Communications Contact - -
Michael J. Malecek LAW
 General Counsel 58 30/06/19
Yvonne M. Tchrakian SEC
 Corporate Secretary - 31/12/13
Karin Walker AUD
 Comptroller/Controller/Auditor 60 19/05/13
Carol Karp LAW
 General Counsel 71 14/12/16

Members of the board

Members of the board TitleAgeSince
Richard Collier BRD
 Director/Board Member 70 19/12/12
Gene Kinney CEO
 Chief Executive Officer 55 30/11/12
Helen Kim BRD
 Director/Board Member 61 31/07/22
Dennis Selkoe BRD
 Director/Board Member 80 21/07/13
Daniel Welch BRD
 Director/Board Member 66 02-20
Shane Cooke BRD
 Director/Board Member 61 19/12/12
Karl Härfstrand BRD
 Director/Board Member 66 28/06/15
Lars Ekman CHM
 Chairman 74 19/12/12
Oleg Nodelman BRD
 Director/Board Member 47 02/12/19
Paula Cobb BRD
 Director/Board Member 51 30/06/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 53,720,455 47,039,852 ( 87.56 %) 0 87.56 %

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
21.56 %
11,584,280 21.56 % 287 M $
Fidelity Management & Research Co. LLC
14.98 %
8,049,796 14.98 % 199 M $
Woodford Investment Management Ltd.
13.87 %
7,448,790 13.87 % 185 M $
T. Rowe Price International Ltd.
7.888 %
4,237,351 7.888 % 105 M $
BlackRock Advisors LLC
6.578 %
3,533,504 6.578 % 88 M $
William P Scully
6.520 %
3,502,481 6.520 % 87 M $
Todd W Fennell
5.848 %
3,141,459 5.848 % 78 M $
STATE STREET CORPORATION
5.135 %
2,758,564 5.135 % 68 M $
Wellington Management Co. LLP
4.829 %
2,594,102 4.829 % 64 M $
Janus Henderson Investors US LLC
3.790 %
2,035,984 3.790 % 50 M $

Company contact information

Prothena Corp. Plc

77 Sir John Rogersons Quay Grand Canal Docklands

2, Dublin

+353 1 236 2500

http://www.prothena.com
address Prothena Corporation plc(PRTA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for Prothena Corporation plc

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.87 USD
Average target price
66.09 USD
Spread / Average Target
+216.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PROTHENA CORPORATION PLC Stock Prothena Corporation plc
-39.32% 1.12B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.57% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.74% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-15.31% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.43% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.29% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.53% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PRTA Stock
  4. Company Prothena Corporation plc